聚乙二醇化干扰素α-2b联合利巴韦林治疗慢性丙型病毒性肝炎的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 聚乙二醇化干扰素α-2b联合利巴韦林治疗慢性丙型病毒性肝炎的临床观察
TITLE:
摘要: 目的:观察聚乙二醇化干扰素(PEG IFN)α-2b联合利巴韦林治疗慢性丙型病毒性肝炎(CHC)的疗效和安全性。 方法: 29例CHC患者随机分为观察组(20例)和对照组(9例)。观察组患者给予PEG IFN α-2b注射液(体质量<65 kg给予40 μg,体质量≥65 kg给予50 μg),每周1次,皮下注射+利巴韦林胶囊(体质量<65 kg给予750 mg,65~84 kg 给予900 mg,≥85 kg给予1 050 mg),口服,每日3次。对照组患者给予干扰素α-2b(IFNα-2b)注射液300万单位,每周3次+皮下注射+利巴韦林(用法用量同观察组)。两组均治疗48周,治疗结束后随访24周。观察两组患者治疗48周时的终点应答率(ETR)、丙型肝炎病毒核糖核酸(HCV RNA)阴转率、丙氨酸转氨酶(ALT)复常率、HCV RNA阳转率、ALT反弹率及随访24周结束时的持续应答率(SVR)、HCV RNA持续阴转率、ALT持续复常率,HCV基因型分布情况及不良反应发生情况。结果:两组患者基因型分布、治疗48周时ETR、HCV RNA阴转率、ALT复常率、HCV RNA阳转率、ALT反弹率,随访24周结束时SVR、HCV RNA持续阴转率、ALT持续复常率及不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:PEG INFα-2b联合利巴韦林与IFNα-2b联合利巴韦林治疗CHC的疗效与安全性均相当。
ABSTRACT: OBJECTIVE: To observe the efficacy and safety of PEG-interferon α-2b combined with ribavirin in the treatment of chronic hepatitis C (CHC). METHODS:29 patients with CHC were randomly divided into control group (9 cases) and observation group (20 cases). Observation group was 40 μg PEG IFN α-2b for patients with more than 65 kg body mass and 50 μg for no less than 65 kg, once a week, subcutaneously+750 mg ribavirin for patients with more than 65 kg body mass, 900 mg for 65-84 kg and 1 050 mg for no less than 85 kg, orally, 3 times a day. Control group was given 3 millionunits of IFNα-2b, 3 times a week, subcutaneously+ribavirin (the same dosage with observation group). All patients treated for 24weeks. End response rate (ETR), hepatitis C virus ribonucleic acid (HCV RNA) negative rate, alanine aminotransferase(ALT) normalization rate, HCV RNA positive rate and ALT rebounded rate after 48 weeks treatment, clinical efficacy [sustained response rate (SVR), HCV RNA continued negative rate, ALT continued normalization rate)], HCV genotype distribution and incidence of adverse reactions after 24 weeks follow-up in 2 groups were observed. RESULTS: There were no significant differences in the genotype distribution, ETR and HCV RNA negative rates, ALT normalization rate, HCV RNA positive rate, ALT rebounded rate after 48 weeks treatment, and SVR and HCV RNA continued negative rates, ALT continued normalization rate and incidence of adverse reactions after 24 weeks follow-up between 2 groups(P>0.05). CONCLUSIONS: PEG INFα-2b has similar efficacy and safety with INFα-2b combined with ribavirin in the treatment of CHC.
期刊: 2016年第27卷第9期
作者: 范晶华,高柳青,王宏图,刘怀鄂,迟晓伟,韦嘉
AUTHORS: FAN Jinghua,GAO Liuqing,WANG Hongtu,LIU Huaie,CHI Xiaowei,WEI Jia
关键字: 慢性丙型病毒性肝炎;聚乙二醇;干扰素α-2b;利巴韦林;疗效;安全性
KEYWORDS: Chronic hepatitis C; Polyethylene glycol; Interferon α-2b; Ribavirin; Efficacy; Safety
阅读数: 422 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!